Market access is increasingly shaping biopharma decisions earlier in the lifecycle. This article explores how policy uncertainty, evidence expectations, and access strategy are influencing development, investment, and long-term value realization.
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.
Congress is considering changes that would significantly alter how Pharmacy Benefit Managers (PBMs) are compensated in commercial insurance. See our report and full analysis.
How a pharmaceutical company built a compliant, scalable 340B contract pharmacy program.
Magnolia Market Access released its fifth iteration of the IRA Payer Insights Survey in the summer of 2025 to understand how the IRA will affect the Medicare Part D program, including beneficiary premiums, formulary coverage, and contract negotiations for manufacturers and payers.
Find out how one manufacturer turned formulary complexity and policy uncertainty into strategic advantage using Magnolia Market Access’ Part D Formulary Databook.
As Medicare Part D plans adopt stricter utilization management, raise cost-sharing, and adjust tier placements, manufacturers face growing challenges in maintaining access. A data-driven formulary coverage assessment helps teams evaluate product positioning, benchmark competitors, and prepare for policy impacts — turning complexity into actionable strategy.
The Medicare Part D landscape is shifting fast. With IRA and H.R.1 driving formulary instability, manufacturers face rising deductibles, tighter utilization management, and new premium dynamics. Learn how Magnolia’s Part D Formulary Databook helps teams anticipate these changes and plan with confidence.
See how Magnolia Market Access helped a manufacturer overcome coding gaps, payer unfamiliarity, and site readiness challenges to launch the first FDA-approved therapy in a rare disease — creating a replicable, gold-standard access model.
Survey of 100 U.S. physicians uncovers key insights on how international HTA frameworks—especially Germany’s—undervalue chronic disease therapies. Explore the full infographic.